急性白血病骨髓单个核细胞糖基化磷脂酰肌醇特异性磷脂酶D的表达(英文)

Glycosylphosphatidilinoditol-specific phospholipase D expression in bone marrow mononuclear cells derived from acute leukemia patients

背景:据作者查新检索,国内外有关急性白血病骨髓单个核细胞糖基化磷脂酰肌醇特异性磷脂酶D活性及mRNA表达与白血病类型、患者肝脾淋巴结肿大关系的报道罕见。目的:探讨糖基化磷脂酰肌醇特异性磷脂酶D的表达与急性白血病类型、急性髓系白血病患者肝脾淋巴结肿大的关系。方法:急性髓系白血病组骨髓标本43例,急性淋巴细胞白血病组骨髓标本28例,以21例健康志愿者作为正常对照组。密度梯度离心法获得骨髓单个核细胞,用GPI锚定的胎盘碱性磷酸酶作为底物,Triton-X114分相法检测糖基化磷脂酰肌醇特异性磷脂酶D的活性,半定量RT-PCR法检测糖基化磷脂酰肌醇特异性磷脂酶DmRNA的表达,并分析糖基化磷脂酰肌醇特异性磷脂酶D活性和mRNA表达水平与急性白血病类型、急性髓系白血病患者肝脾淋巴结肿大的关系。结果与结论:与正常对照组比较,急性髓系白血病组骨髓单个核细胞糖基化磷脂酰肌醇特异性磷脂酶D活性和mRNA表达均明显升高(P<0.01);急性淋巴细胞白血病组骨髓单个核细胞糖基化磷脂酰肌醇特异性磷脂酶D活性和mRNA表达均明显降低(P<0.01)。在43例急性髓系白血病患者中,13例患者检查发现有肝脾淋巴结肿大,30例患者检查无肝脾淋巴结肿大,无肝脾淋巴结肿大标本骨髓单个核细胞糖基化磷脂酰肌醇特异性磷脂酶D活性和mRNA表达均明显高于有肝脾淋巴结肿大标本(P<0.05)。结果证实急性白血病骨髓单个核细胞糖基化磷脂酰肌醇特异性磷脂酶D的活性与mRNA变化一致,其表达水平与急性白血病类型及急性髓系白血病患者有无肝脾和/或淋巴结肿大有关。

BACKGROUND：The correlation of gycosylphosphatidilinoditol-specific phospholipase D （GPI-PLD） activity,mRNA expression to leukemia type,hepatosplenomegaly and/or lymphadenopathy has been rarely reported.OBJECTIVE：To explore the correlation of GPI-PLD expression to leukemia type and hepatosplenomegaly and/or lymphadenopathy of acute myeloid leukemia （AML） patients.METHODS：Fresh bone marrow specimens were obtained from 43 newly diagnosed AML patients,28 acute lymphocytic leukemia （ALL） patients,and 21 normal persons.Bone marrow mononuclear cells were harvested by density gradient centrifugation.GPI-anchored human placent alkaline phosphatase was used as substrate.GPI-PLD activity was determined bytriton-X114 phase partitioning procedure.GPI-PLD mRNA expression was detected by semi-quantitative RT-PCR.The relationship of GPI-PLD activity,mRNA expression and leukemia type,hepatosplenomegaly and/or lymphadenopathy was analyzed.RESULTS AND CONCLUSION：Compared with control group,GPI-PLD activity and mRNA expression in bone marrow mononuclear cells were significantly higher in AML group （P 0.01）,while they were significantly lower in the ALL group （P 0.01）.Of 43 patients with AML patients,13 patients had hepatosplenomegaly and/or lymphadenopathy.The GPI-PLD activity （%） and mRNA expression were significantly higher in AML patients without hepatosplenomegaly and lymphadenopathy than those patients with hepatosplenomegaly and/or lymphadenopathy （P 0.05）.These results demonstrated that GPI-PLD activity alteration is consistent with GPI-PLD mRNA expression in AML patients,and the expression levels correlate to leukemia type and hepatosplenomegaly and/or lymphadenopathy of AML patients.